AbbVie (ABBV) Cash & Equivalents (2012 - 2026)

AbbVie (ABBV) has reported Cash & Equivalents for 15 consecutive years, with $9.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 81.47% year-over-year to $9.4 billion; the TTM figure through Mar 2026 stood at $9.4 billion (up 81.47% YoY), while the FY2025 annual figure was $5.2 billion, down 5.34% from the prior year.
• Cash & Equivalents rose to $9.4 billion in Q1 2026 per ABBV's latest filing, from $5.2 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $18.1 billion in Q1 2024 and bottomed at $5.2 billion in Q1 2025.
• Historically, Cash & Equivalents has averaged $9.0 billion across 5 years, with a median of $8.5 billion in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 169.21% — and 2025, when it sank 71.36%.
• AbbVie's Cash & Equivalents stood at $9.2 billion in 2022, then soared by 39.27% to $12.8 billion in 2023, then slumped by 56.89% to $5.5 billion in 2024, then slipped by 5.34% to $5.2 billion in 2025, then jumped by 79.59% to $9.4 billion in 2026.
• Business Quant data shows ABBV's Cash & Equivalents at $9.4 billion in Q1 2026, $5.2 billion in Q4 2025, and $5.6 billion in Q3 2025.